新生儿B族链球菌感染预防策略的研究进展

仝净净; 姚开虎; 杨永弘

doi:10.7499/j.issn.1008-8830.2014.10.025

PDF(1596 KB)

HTML

中国当代儿科杂志 ›› 2014, Vol. 16 ›› Issue (10) : 1075-1080. DOI: 10.7499/j.issn.1008-8830.2014.10.025

综述

新生儿B族链球菌感染预防策略的研究进展

仝净净, 姚开虎, 杨永弘

作者信息 +

Research advance in prevention policies of neonatal group B Streptococcus infection

TONG Jing-Jing, YAO Kai-Hu, YANG Yong-Hong

Author information +

文章历史 +

摘要

B 族链球菌可引起新生儿早发型和晚发型疾病，主要危险因素是母亲胃肠道和生殖道的定植。目前对存在危险因素的妊娠妇女有两种筛选方案：高危因素评估方案和普遍筛查方案；美国等国家采取产时抗生素预防性治疗措施，使早发型B 族链球菌疾病的发病率大幅度降低，但对晚发型疾病的发病率影响不大。抗生素预防性治疗首选青霉素，对青霉素过敏者需依据菌株药敏结果选择药物。抗生素预防性治疗措施存在一定的弊端，需积极研发其他的预防措施来预防B 族链球菌感染。

Abstract

Group B Streptococcus (GBS) is responsible for two distinct clinical syndromes in the newborn period categorised as either early- or late-onset GBS disease. Maternal GBS colonization of gastrointestinal tract or vaginal is the major risk factor for GBS diseases. There are two main strategies for identifying women at risk of giving birth to a GBS-infected infant: universal screening strategy and risk-based assessment. In the United States and other countries, the implementation of maternal intrapartum antibiotic prophylaxis policies has significantly reduced the incidence of early-onset neonatal GBS disease, but has little effect on the incidence of late-onset GBS disease. Penicillin is the first choice for antibiotic prophylaxis treatment. GBS strains which are isolated from pregnant women who are allergic to penicillin should undergo antibiotic susceptibility testing. Antibiotic prophylaxis measures have some disadvantages, so researchers should actively develop other precautions to prevent GBS infection.

导出引用

仝净净, 姚开虎, 杨永弘. 新生儿B族链球菌感染预防策略的研究进展[J]. 中国当代儿科杂志. 2014, 16(10): 1075-1080 https://doi.org/10.7499/j.issn.1008-8830.2014.10.025

TONG Jing-Jing, YAO Kai-Hu, YANG Yong-Hong. Research advance in prevention policies of neonatal group B Streptococcus infection[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(10): 1075-1080 https://doi.org/10.7499/j.issn.1008-8830.2014.10.025

参考文献

[1] Le Doare K, Heath PT. An overview of global GBSepidemiology [J]. Vaccine, 2013, 31 (Suppl 4): D7-D12.
[2] Perinatal group B streptococcal disease after universal screeningrecommendations-United States, 2003-2005[J]. MMWR MorbMortal Wkly Rep, 2007, 56(28): 701-705.
[3] Melin P. Neonatal group B streptococcal disease: frompathogenesis to preventive strategies[J]. Clin Microbiol Infect,2011, 17(9): 1294-1303.
[4] Edmond KM, Kortsalioudaki C, Scott S, et al. Group Bstreptococcal disease in infants aged younger than 3 months:systematic review and meta-analysis[J]. Lancet, 2012,379(9815): 547-556.
[5] Yu HW, Lin HC, Yang PH, et al. Group B streptococcal infectionin Taiwan: maternal colonization and neonatal infection[J].Pediatr Neonatol, 2011, 52(4): 190-195.
[6] Jordan HT, Farley MM, Craig A, et al. Revisiting the need forvaccine prevention of late-onset neonatal group B streptococcaldisease: a multistate, population-based analysis[J]. Pediatr InfectDis J, 2008, 27(12): 1057-1064.
[7] Barbadoro P, Marigliano A, Savini S, et al. Group BStreptococcal sepsis: an old or ongoing threat?[J]. Am J InfectControl, 2011, 39(8): e45-e48.
[8] Verani JR, Mcgee L, Schrag SJ. Prevention of perinatal group Bstreptococcal revised disease—guidelines from CDC, 2010[J].MMWR Recomm Rep, 2010, 59(RR-10): 1-36.
[9] Koenig JM, Keenan WJ. Group B streptococcus and early-onsetsepsis in the era of maternal prophylaxis[J]. Pediatr Clin NorthAm, 2009, 56(3): 689-708.
[10] Randis TM, Polin RA. Early-onset group B Streptococcal sepsis:new recommendations from the Centres for Disease Control andPrevention[J]. Arch Dis Child Fetal Neonatal Ed, 2012, 97(4):F291-F294.
[11] Chang LY. Maternal colonization and neonatal group Bstreptococcal infection: time to universal screening andintrapartum chemoprophylaxis in Taiwan?[J]. Pediatr Neonatol,2011, 52(4): 181-182.
[12] Lu B, Li D, Cui Y, et al. Epidemiology of Group B streptococcusisolated from pregnant women in Beijing, China[J]. ClinMicrobiol Infect, 2014, 20(6): 370-373.
[13] Lo JY. Early-onset group B streptococcus neonatal disease: atarget for prevention?[J]. Hong Kong Med J, 2009, 15(6): 412-413.
[14] Madzivhandila M, Adrian PV, Cutland CL, et al. Serotypedistribution and invasive potential of group B streptococcusisolates causing disease in infants and colonizing maternalnewborndyads[J]. PLoS One, 2011, 6(3): e17861.
[15] Boyer KM, Gotoff SP. Strategies for chemoprophylaxis of GBSearly-onset infections[J]. Antibiot Chemother (1971), 1985, 35:267-280.
[16] Berardi A, Rossi C, Lugli L, et al. Group B streptococcus late-onset disease: 2003-2010[J]. Pediatrics, 2013, 131(2):e361-e368.
[17] Lin FY, Weisman LE, Troendle J, et al. Prematurity is the majorrisk factor for late-onset group B streptococcus disease[J]. JInfect Dis, 2003, 188(2): 267-271.
[18] Johri AK, Paoletti LC, Glaser P, et al. Group B Streptococcus:global incidence and vaccine development[J]. Nat RevMicrobiol, 2006, 4(12): 932-942.
[19] 安晓霞. 新生儿无乳链球菌感染的研究进展[J]. 临床和实验医学杂志, 2012, 11(20): 1670-1671.
[20] Taminato M, Fram D, Torloni MR, et al. Screening for groupB Streptococcus in pregnant women: a systematic review andmeta-analysis[J]. Rev Lat Am Enfermagem, 2011, 19(6): 1470-1478.
[21] Prevention of perinatal group B streptococcal disease: apublic health perspective. Centers for Disease Control andPrevention[J]. MMWR Recomm Rep, 1996, 45(RR-7): 1-24.
[22] Kolkman DG, Rijnders ME, Wouters MG, et al. Implementationof a cost-effective strategy to prevent neonatal early-onset groupB haemolytic streptococcus disease in the Netherlands[J]. BMCPregnancy Childbirth, 2013, 13: 155.
[23] 斯悦, 申阿东, 杨永弘. 预防B 组链球菌感染的新策略[J].中华围产医学杂志, 2001, 4(1): 60-62.
[24] Schrag SJ, Zell ER, Lynfield R, et al. A population-basedcomparison of strategies to prevent early-onset group Bstreptococcal disease in neonates[J]. N Engl J Med, 2002,347(4): 233-239.
[25] Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcaldisease in the era of intrapartum antibiotic prophylaxis[J]. NEngl J Med, 2000, 342(1): 15-20.
[26] Baker CJ, Byington CL, Polin RA. Policy statementrecommendationsfor the prevention of perinatal group Bstreptococcal (GBS) disease[J]. Pediatrics, 2011, 128(3): 611-616.
[27] Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation ofuniversal antenatal screening for group B streptococcus[J]. NEngl J Med, 2009, 360(25): 2626-2636.
[28] Mario MJ, Valenzuela I, Vasquez AE, et al. Prevention of earlyonsetneonatal group B streptococcal disease[J]. Rev ObstetGynecol, 2013, 6(2): 63-68.
[29] Creti R, Berardi A, Baldassarri L, et al. Characteristics ofneonatal GBS disease during a multicentre study (2007-2010)and in the year 2012[J]. Ann Ist Super Sanita, 2013, 49(4): 370-375.
[30] Melin P, Efstratiou A. Group B streptococcal epidemiologyand vaccine needs in developed countries[J]. Vaccine, 2013, 31(Suppl 4): D31-D42.
[31] Mclaughlin K, Crowther C. Universal antenatal group Bstreptococcus screening? The opinions of obstetricians andneonatologists within Australia[J]. Aust N Z J Obstet Gynaecol,2010, 50(5): 410-412.
[32] Gilbert GL, Hewitt MC, Turner CM, et al. Epidemiologyand predictive values of risk factors for neonatal group Bstreptococcal sepsis[J]. Aust N Z J Obstet Gynaecol, 2002,42(5): 497-503.
[33] Paccione KA, Wiesenfeld HC. Guideline adherence forintrapartum group B streptococci prophylaxis in penicillinallergicpatients[J]. Infect Dis Obstet Gynecol, 2013, 2013:917304.
[34] Garland SM, Cottrill E, Markowski L, et al. Antimicrobialresistance in group B streptococcus: the Australianexperience[J]. J Med Microbiol, 2011, 60(Pt 2): 230-235.
[35] Clifford V, Heffernan HM, Grimwood K, et al. Variation inerythromycin and clindamycin resistance patterns between NewZealand and Australian group B streptococcus isolates[J]. AustN Z J Obstet Gynaecol, 2011, 51(4): 328-332.
[36] Blaschke AJ, Pulver LS, Korgenski EK, et al. Clindamycinresistantgroup B Streptococcus and failure of intrapartumprophylaxis to prevent early-onset disease[J]. J Pediatr, 2010,156(3): 501-503.
[37] Neu J. Perinatal and neonatal manipulation of the intestinalmicrobiome: a note of caution[J]. Nutr Rev, 2007, 65(6 Pt 1):282-285.
[38] Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis forthe prevention of perinatal group B streptococcal disease:experience in the United States and implications for a potentialgroup B streptococcal vaccine[J]. Vaccine, 2013, 31 (Suppl 4):D20-D26.
[39] Bauserman MS, Laughon MM, Hornik CP, et al. Group BStreptococcus and Escherichia coli infections in the intensivecare nursery in the era of intrapartum antibiotic prophylaxis[J].Pediatr Infect Dis J, 2013, 32(3): 208-212.
[40] Rappuoli R, Black S. Introduction: addressing the challenge ofgroup B streptococcal disease[J]. Vaccine, 2013, 31 (Suppl 4):D1-D2.
[41] Rodriguez-Granger J, Alvargonzalez JC, Berardi A, et al.Prevention of group B streptococcal neonatal disease revisited.The DEVANI European project[J]. Eur J Clin Microbiol InfectDis, 2012, 31(9): 2097-2104.
[42] Annati E, Roshani M, Arzanlou M, et al. Capsular serotypeand antibiotic resistance of group B streptococci isolated frompregnant women in Ardabil, Iran[J]. Iran J Microbiol, 2012,4(3): 130-135.
[43] Madhi SA, Dangor Z, Heath PT, et al. Considerationsfor a phase-III trial to evaluate a group B Streptococcuspolysaccharide-protein conjugate vaccine in pregnant womenfor the prevention of early- and late-onset invasive disease inyoung-infants[J]. Vaccine, 2013, 31 (Suppl 4): D52-D57.